Go Pro
NASDAQ:BIOL

BIOLASE (BIOL) Stock Price, News & Analysis

BIOLASE logo

About BIOLASE Stock (NASDAQ:BIOL)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
2.58 million shs
Market Capitalization
$581 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BIOLASE, Inc. (NASDAQ: BIOL) is a medical device company specializing in the design, development and manufacture of laser systems for dentistry. The company’s laser platforms enable minimally invasive dental procedures, combining laser energy with water spray to perform both hard‐tissue and soft‐tissue applications. By integrating advanced laser technology into routine dental care, BIOLASE aims to improve patient comfort, reduce the need for anesthesia and shorten procedure times.

The company’s flagship products include the Waterlase® family of erbium lasers and the Epic™ series of diode lasers. Waterlase systems are indicated for a wide range of applications, including cavity preparation, bone surgery, endodontics, periodontal therapy and oral surgery. Epic diode lasers are used primarily for soft‐tissue procedures such as gum recontouring, pain management and bacterial reduction. BIOLASE also offers a comprehensive portfolio of handpieces, tips and accessories to support clinical workflows and practice growth.

Founded in 1984 and headquartered in Irvine, California, BIOLASE has established a global distribution network that spans North America, Europe, Asia and other international markets. The company works with dental equipment dealers, group purchasing organizations and strategic partners to expand market reach and provide training and support to dental professionals. BIOLASE’s research and development efforts are focused on enhancing laser performance, broadening procedural indications and integrating digital dentistry solutions.

AI Generated. May Contain Errors.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIOL Stock News Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
Biolase Inc (BIOLQ)
See More Headlines

BIOL Stock Analysis - Frequently Asked Questions

BIOLASE, Inc. (NASDAQ:BIOL) posted its earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative trailing twelve-month return on equity of 1,782.73% and a negative net margin of 41.65%.

BIOLASE shares reverse split before market open on Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN).

Company Calendar

Last Earnings
11/10/2021
Today
8/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
CIK
811240
Employees
160
Year Founded
1987

Profitability

EPS (Trailing Twelve Months)
($14.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.63 million
Net Margins
-41.65%
Pretax Margin
-41.56%
Return on Equity
-1,782.73%
Return on Assets
-55.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.71
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$48.83 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
33,407,000
Free Float
33,317,000
Market Cap
$581 thousand
Optionable
Not Optionable
Beta
0.67

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:BIOL) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners